NK-lysin peptides ameliorate viral encephalopathy and retinopathy disease signs and provide partial protection against nodavirus infection in European sea bass
Loading...
Publication date
Advisors
Research group
Center
Abstract
Antimicrobial peptides (AMP) comprise a wide range of small molecules with direct antibacterial activity and
immunostimulatory role and are proposed as promising substitutes of the antibiotics. Additionally, they also
exert a role against other pathogens such as viruses and fungi less evaluated. NK-lysin, a human granulysin
orthologue, possess a double function, taking part in the innate immunity as AMP and also as direct effector in
the cell-mediated cytotoxic (CMC) response. This molecule is suggested as a pivotal molecule involved in the
defence upon nervous necrosis virus (NNV), an epizootic virus provoking serious problems in welfare and health
status in Asian and Mediterranean fish destined to human consumption. Having proved that NK-lysin derived
peptides (NKLPs) have a direct antiviral activity against NNV in vitro, we aimed to evaluate their potential use as
a prophylactic treatment for European sea bass (Dicentrarchus labrax), one of the most susceptible cultured-fish
species. Thus, intramuscular injection of synthetic NKLPs resulted in a very low transcriptional response of some
innate and adaptive immune markers. However, the injection of NKLPs ameliorated disease signs and increased
fish survival upon challenge with pathogenic NNV. Although NKLPs showed promising results in treatments
against NNV, more efforts are needed to understand their mechanisms of action and their applicability to the
aquaculture industry.
Unesco Subjects
Bibliographic citation
Valero, Y., González-Fernández, C., Cárdenas, C., Guzmán, F., León, R., & Cuesta, A. (2021). NK-lysin peptides ameliorate viral encephalopathy and retinopathy disease signs and provide partial protection against nodavirus infection in European sea bass. In Antiviral Research (Vol. 192, p. 105104). Elsevier BV. https://doi.org/10.1016/j.antiviral.2021.105104














